CNS

Recent breakthroughs in scientific understanding, diagnostic capabilities and delivery machinery have ignited a resurgence of investment and momentum into CNS drug development. However, with high disease heterogeneity, clinical setbacks, and rapidly growing unmet patient needs, addressing some of the most challenging neurodegenerative, neuropsychiatric and neuromuscular disorders requires continued commitment and innovation.